Association of Second Anti-hypertensive Agent with Outcomes in People with CKD on ACEi/ARB Therapy
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are first-line treatment for hypertension in chronic kidney disease (CKD). However, guidelines do not recommend subsequent medication classes if additional blood pressure-lowering effect is desired. METHODS: This target trial emulation using national outpatient data from the Veterans Health Administration from January 1, 2010, to December 31, 2016, included adults with non-dialysis CKD stages G1-G5 on an ACEi/ARB who initiated treatment with a second antihypertensive medication, classified as a thiazide diuretic, loop diuretic, calcium channel blocker, or β-blocker. Outcomes included composite cardiovascular events (fatal or nonfatal myocardial infarction or stroke, hospitalization for heart failure, coronary revascularization), all-cause death, and composite kidney outcomes (dialysis initiation, kidney transplantation, sustained creatinine doubling). Clinically important characteristics were included as covariates in the analysis. RESULTS: Of 150,369 individuals already on ACEi/ARB treatment, 45,836 (30%) were prescribed a thiazide diuretic, 17,589 (12%) a loop diuretic, 33,172 (22%) a calcium channel blocker, and 53,772 (36%) a β-blocker. Those receiving thiazide diuretics and calcium channel blockers had the highest baseline blood pressure. Those receiving loop diuretics were more likely to have more advanced CKD or heart failure. Over a median (IQR) follow-up of 1282 (621, 1979) days, compared to thiazide diuretics, cardiovascular event risk was higher for calcium channel blockers, aHR 1.18 (95% CI 1.15-1.22), β-blockers, aHR 1.63 (95% CI 1.58-1.67), and loop diuretics, aHR 1.97 (95% CI 1.90-2.04). Composite kidney outcomes were also higher with calcium channel blockers, aHR 1.42 (95% CI 1.33-1.52), β-blockers, aHR 1.13 (95% CI 1.06-1.21), and loop diuretics, aHR 1.98 (95% CI 1.83-2.15). CONCLUSIONS: Adding a thiazide diuretic rather than a calcium channel blocker, β-blocker, or loop diuretic on top of ACEi/ARB treatment was associated with favorable clinical outcomes among people with CKD.
Authors
- Wolfgang C. Winkelmayer (ORCID: https://orcid.org/0000-0002-5272-425X)
- L. Parker Gregg (ORCID: https://orcid.org/0000-0002-5469-367X)
- S. Susan Hedayati (ORCID: https://orcid.org/0000-0001-8850-4729)
- Vijay Nambi (ORCID: https://orcid.org/0000-0002-4237-0267)
- Sankar Dass Navaneethan (ORCID: https://orcid.org/0000-0002-4953-7795)
- Hui Yang (ORCID: https://orcid.org/0000-0001-9416-7829)
- Carlos A. Álvarez (ORCID: https://orcid.org/0000-0002-9512-1870)
- Christine Vu (ORCID: https://orcid.org/0009-0001-4241-264X)
- Aaron Perkins
Institutions
- Michael E. DeBakey VA Medical Center (US)
- Baylor College of Medicine (US)
- Health Services Research & Development (US)
- Stony Brook Medicine (US)
- VA North Texas Health Care System (US)
- Center for Innovation (US)
- Stony Brook University (US)
- The University of Texas Southwestern Medical Center (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- Journal of the American Society of Nephrology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1681/asn.0000001313
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00